Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma (IDRIS)
Phase III Randomised Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
Sponsor: Cancer Research UK
Listed as NCT02544308, this PHASE3 trial focuses on Plasmacytoma and remains ongoing. Sponsored by Cancer Research UK, it has been updated 9 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2021 — Jan 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Nov 2019 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jun 2018 — Nov 2019 [monthly]
Recruiting PHASE3
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Jun 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Research UK
- Celgene
- University College, London
For direct contact, visit the study record on ClinicalTrials.gov .